TLX250-TRAP

N/A

Report date: 2026/01/23 18:05:11

Base Information

Drug NameTLX250-TRAP
Drug Alias NameLu-TLX250-TRAPIsotope lutetium-177 (Lu-177)-labeled TLX250-TRAPTLX250-TRAPTLX250TRAP
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > AntibodyRadiation-emitting products > Radionuclide Drug Conjugates +[6] 
Mechanisms of ActionTransforming growth factor beta 2 modulatorsAnti-Carbonic anhydrase IX
TargetsTransforming growth factor beta 2Carbonic anhydrase IX
Therapy Area/IndicationsTriple Negative Breast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesTelix Pharmaceuticals LtdUniversity Of Wisconsin-MadisonUniversity Of Oxford
China Registration ClassN/A

Develop Information

Active CompaniesTelix Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A